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Neurometabolic disorders are markedly heterogeneous, both clinically and genetically, and are characterized by variable neuro-
logical dysfunction accompanied by suggestive neuroimaging or biochemical abnormalities. Despite early specialist input, delays in
diagnosis and appropriate treatment initiation are common. Next-generation sequencing approaches still have limitations but are
already enabling earlier and more efﬁcient diagnoses in these patients. We designed a gene panel targeting 614 genes causing
inborn errors of metabolism and tested its diagnostic efﬁcacy in a paediatric cohort of 30 undiagnosed patients presenting with
variable neurometabolic phenotypes. Genetic defects that could, at least partially, explain observed phenotypes were identiﬁed in
53% of cases. Where biochemical abnormalities pointing towards a particular gene defect were present, our panel identiﬁed
diagnoses in 89% of patients. Phenotypes attributable to defects in more than one gene were seen in 13% of cases. The ability
of in silico tools, including structure-guided prediction programmes to characterize novel missense variants were also interrogated.
Our study expands the genetic, clinical and biochemical phenotypes of well-characterized (POMGNT1, TPP1) and recently
identiﬁed disorders (PGAP2, ACSF3, SERAC1, AFG3L2, DPYS). Overall, our panel was accurate and efﬁcient, demonstrating
good potential for applying similar approaches to clinically and biochemically diverse neurometabolic disease cohorts.
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Abbreviations: IEM = inborn errors of metabolism; NGS = next-generation sequencing; WES = whole-exome sequencing; WGS =
whole-genome sequencing
Introduction
Inborn errors of metabolism (IEM) are markedly heteroge-
neous, both clinically and genetically, with more than 600
genes known to cause disease. In the presence of neuro-
logical dysfunction, which is not only common in IEM
but also often the most prominent phenotypic feature,
these patients are frequently labelled as having ‘probable
neurometabolic disease’, especially if suggestive neuroima-
ging or laboratory ﬁndings co-exist. The challenges when
diagnosing neurometabolic disorders are largely attribut-
able to the clinical and genetic heterogeneity (including
often non-speciﬁc or atypical presentations early on in the
disease course) and lack of clinical awareness of rare enti-
ties. Patients with suspected neurometabolic disease are fre-
quently referred to specialist centres and undergo extensive
and often invasive diagnostic testing. Despite this, diagnos-
tic delays or difﬁculties establishing a deﬁnitive diagnosis
are commonly encountered, with many such patients at-
tending secondary and tertiary neurology clinics remaining
undiagnosed (Verity et al., 2010).
Timely diagnosis of neurometabolic disease is crucial, es-
pecially for those disorders that are treatable or manage-
able, with early initiation of treatment often resulting in
improved outcomes. Next-generation sequencing (NGS)
has revolutionized the diagnostic approach to such condi-
tions (Nemeth et al., 2013; Martin et al., 2014) and helped
to reduce the number of tests required for a diagnosis to be
established. However, despite the continuous progress
made in the ﬁeld, there are still limitations to the approach,
including access to NGS technology (especially in a non-
specialist setting), costs, incomplete coverage of candidate
genes and generation of large amounts of data that are
difﬁcult to interpret. Whole-exome sequencing (WES) and
whole-genome sequencing (WGS) studies are primarily
offered either in research laboratories or in a commercial
setting, and have not yet been fully integrated into the clin-
ical genetics services of many healthcare systems world-
wide. An alternative NGS method, gene panel testing, has
recently become available in clinical services and offers tar-
geted testing of candidate genes. An extended genetic panel
approach to investigating IEM might be advantageous
(Saudi Mendeliome Group, 2015) due to reduced times
required for data processing and increased coverage depth
compared to WES and WGS. Our objective was to inves-
tigate the utility of this approach by designing an IEM gene
panel and applying it to patients presenting with a wide
array of neurometabolic phenotypes. We discuss the
panel’s effectiveness in establishing a diagnosis, the clinical
implications of its use as well as potential pitfalls of using
broad-scale genetic testing. We also consider the predictive
value of in silico tools commonly used for characterization
of novel variants and investigate whether mapping of de-
tected variants to known 3D protein structures can help
further elucidate their signiﬁcance.
Materials and methods
Patients
This study was approved by the National Research Ethics
Service (NRES) Committee London – Bloomsbury (REC refer-
ence: 13/LO/0168). We recruited patients from a single UK
tertiary centre’s neurometabolic disease clinics presenting
with a range of neurological features such as developmental
delay, macro or microcephaly, neurological regression, ataxia,
epilepsy and/or organomegaly with or without other diagnostic
indicators [including suggestive biochemical marker(s) or neu-
roimaging abnormalities]. All participants had undergone ex-
tensive previous investigations including multiple standard and
specialized biochemical tests, invasive procedures (e.g. muscle
and/or skin biopsy, lumbar puncture) and targeted gene testing
but lacked a deﬁnitive molecular diagnosis. Thirty patients
were included (Tables 1–3). First, we recruited 21 patients
with suspected IEM but absence of speciﬁc clinical ﬁndings
or biochemical pointers towards a particular disorder.
Additionally, we included nine cases where biochemical ﬁnd-
ings indicated a particular disorder or group of disorders, not
only to investigate the utility of this approach in more speciﬁc
presentations but also because similar biochemical abnormal-
ities could result from mutations in multiple genes. Finally, for
panel validation purposes, we additionally recruited 13 pa-
tients with a known genetic diagnosis (Supplementary Table
1). Written informed consent was obtained in all cases.
Gene capture, sequencing
and variant analysis
A custom HaloPlex target enrichment system (Agilent) was
used to capture 614 genes, covering 16 broad classes of IEM
(Supplementary material). Sequencing was performed using the
HiSeq 2500 platform (Illumina). Sequence variants with puta-
tively deleterious effects were conﬁrmed by Sanger sequencing
(Supplementary Table 4). To interrogate for potential patho-
genicity in identiﬁed variants, we investigated whether variants
had been reported previously as pathogenic, their frequency in
the population, segregation within the family (where samples
were available) and predicted functional impact utilizing SIFT
(http://sift.bii.a-star.edu.sg/), PolyPhen-2 (http://genetics.bwh.
harvard.edu/pph2/) and Combined Annotation Dependent
Depletion (CADD) (http://cadd.gs.washington.edu/). Where
possible, missense variants were mapped to known 3D protein
structures and compared to in silico ﬁndings (Supplementary
Table 5).
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Results
Panel validation
Nineteen of 20 pathogenic sequence variants were identi-
ﬁed in the 13 genetically diagnosed control samples
(Supplementary Table 1). These included seven heterozy-
gous and ﬁve homozygous missense, two heterozygous
splice site mutations, a heterozygous single base insertion
and four deletions ranging in size from 2bp to 6 kbp.
The homozygous 37-amino acid deletion in Patient D6
was not identiﬁed. Seven of 20 variants had not been pre-
viously reported in the literature.
Clinical characteristics of
undiagnosed cohort
Age ranged from 1 to 20 years (mean 7.2 years, median 6
years). Only 9/30 patients (Patients B1–B9, Tables 1–3)
had abnormal biochemistry suggestive of an underlying
genetic diagnosis, despite previous extensive testing in all
cases. Our panel identiﬁed 21 variants in 16 patients, of
which only seven had previously been reported in the lit-
erature (Reichardt et al., 1991; 1992; Shen et al., 1996;
Wohlers et al., 1999; Aoshima et al., 2001; Yoshida et al.,
2001; Santer et al., 2005). Ten variants were classiﬁed as
pathogenic, 10 as likely pathogenic and one of uncertain
signiﬁcance (Richards et al., 2015) (Supplementary Table
5). Variants included 15 missense, two nonsense, three in-
sertions/deletions and one splice site mutation. Identiﬁed
variants could at least partially explain the observed clin-
ical phenotype in all cases.
Of nine patients with previous biochemical testing point-
ing towards a diagnosis, identiﬁcation of pathogenic vari-
ants was possible for eight (88.8%). Parental DNA to
check segregation within families was not available. We
were unable to identify any potential pathogenic variants
in Patient B9, whose biochemical proﬁle suggested hyper-
prolinaemia type II and, in whom, a homozygous complex
insertion/deletion event resulting in a frameshift and pre-
mature stop codon in ALDH4A1 was subsequently iden-
tiﬁed via Sanger sequencing. Otherwise, in most other
cases, two pathogenic variants were identiﬁed in each can-
didate gene.
We were also able to attain a molecular genetic diagno-
sis in 8/21 (38%) of patients without a biochemical
marker pointing towards a speciﬁc genetic diagnosis
(Tables 1–3). Two pathogenic (or likely pathogenic) vari-
ants were identiﬁed for each candidate gene. All variants
were conﬁrmed by Sanger sequencing in probands and
family members where possible. Detailed clinical descrip-
tions of these patients are given in the Supplementary ma-
terial. In Patients B6, B7 and U2, the identiﬁed variants
could explain the biochemical abnormalities but not other
clinical features observed, indicating the presence of other,
as yet unidentiﬁed gene defects. Additionally, Patient U7T
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had pathogenic variants identiﬁed in ALDOB and TPP1,
while the clinical and biochemical phenotype was consistent
with simultaneous presence of mutations in both genes
(Supplementary material).
3D structure analysis
3D structural analysis of identiﬁed variants was performed
using the ICM-Pro software (Molsoft LLC), when struc-
tural data were available for the proteins (Patients B2, U7
and U8) or for ‘close homologues/orthologues’ (Patients B8
and U4) (Supplementary Table 6). The impact of the amino
acid substitution for six missense variants, all predicted to
be deleterious and probably/possibly damaging by SIFT
and PolyPhen-2, was determined by mapping them onto
the wild-type structures and inspecting potential changes
in bonding interactions, packing and secondary structures
due to the amino acid substitution. In all cases, our struc-
ture-guided ﬁndings concurred with in silico prediction
software, further supporting variant pathogenicity.
Discussion
In our study, we investigated the utility of an extended gene
panel in diagnosing patients with neurometabolic disorders.
Due to the marked clinical, biochemical and genetic hetero-
geneity encountered in neurometabolic disease, targeted
gene testing is often not advantageous, economical or efﬁ-
cient. The panel described in our study was shown to be a
powerful tool that enhances the diagnostic ability in the
clinical setting. It covers 614 genes, including the vast ma-
jority of genes currently known to cause neurometabolic
disease, hence sharing similarities with WES approaches
but with the added advantage of more optimal coverage
of targeted areas (Kammermeier et al., 2014). Indeed,
coverage of targeted areas was similar or superior to that
reported in other gene panels despite the large number of
genes covered (Nemeth et al., 2013; Yohe et al., 2015).
Moreover, the diagnosis rate in our study was comparable
to, or higher than, that reported in similar approaches re-
cently applied in other patient groups exhibiting phenotypic
heterogeneity (Kammermeier et al., 2014; Sommen et al.,
2016; Trump et al., 2016).
We investigated patients with a wide array of, and often
non-speciﬁc, neurometabolic symptomatology and were
able to identify disease-causing mutations in a large
number of cases. We interrogated 30 cases with no deﬁni-
tive molecular diagnosis despite having had all the path-
ology laboratory (including metabolic biochemistry) tests
and imaging modalities that a tertiary referral metabolic
centre considered might lead to a diagnosis. Of the 21/30
patients lacking pointers towards an underlying molecular
diagnosis, pathogenic variants that explained all the clinical
and biochemical ﬁndings were identiﬁed in seven (33%)
and some of the phenotypic features in one (5%); demon-
strating the effectiveness of this approach in a clinically
heterogeneous, diagnostically challenging cohort. In these
patients, there was no clear phenotypic or biochemical fea-
ture associated with higher or lower diagnostic rates on our
panel, although study numbers preclude further conclu-
sions. Additionally, where suggestive biochemical abnorm-
alities existed, our panel efﬁciently led to a deﬁnitive
genetic diagnosis in 8/9 cases. However, it is important to
note that our cohort was recruited through a single tertiary
referral centre, which may lead to selection bias. Therefore,
further studies using large cohorts of patients consecutively
enrolled from multiple metabolic medicine centres are war-
ranted to establish the exact sensitivity and speciﬁcity of
our panel. Nevertheless, we demonstrate that our extended
panel approach, with subsequent focus on candidate
gene(s), can be an initial relatively cost-effective approach
to investigate patients with suspected neurometabolic dis-
orders. Moreover, although applied to a paediatric cohort,
our approach would arguably be even more useful in adult
populations, where neurometabolic phenotypes can be even
more atypical, presentations more variable and biochemical
phenotypes even more subtle. Indeed, many lysosomal stor-
age, mitochondrial, peroxisomal and other metabolic dis-
orders present atypically in adults. For example,
adrenoleukodystrophy can present as early-onset dementia
(Kumar et al., 1995). Patients with urea cycle disorders,
organic acidaemias and Niemann Pick type C can also ex-
hibit psychiatric manifestations (Sedel et al., 2007). Thus, a
comprehensive panel approach can have high utility in pa-
tients presenting with unexplained/atypical psychiatric or
neurological manifestations.
Our study expands the genotypic and phenotypic spec-
trum of several disorders but also re-emphasizes the com-
plexity of diagnosing patients with IEM. Patient U1
presented with a multi-system disorder and signiﬁcant my-
opathy; however, due to unremarkable brain imaging and a
non-diagnostic muscle biopsy (Supplementary Fig. 1), the
diagnosis of POMGNT1-related dystroglycanopathy was
delayed. Although uncommon, normal glycosylated a-dys-
troglycan immunoﬂuorescence staining has been reported
previously in POMGNT1 patients (Clement et al., 2008).
Patient U7 had neurodevelopmental difﬁculties and hyper-
reﬂexia, hence representing a mild TPP1-related phenotype
compared to those typically reported in the literature
(Breedveld et al., 2004; Sun et al., 2013), whereas his ab-
normal transferrin isoelectric focusing was attributable to
the ALDOB mutations. Indeed, following variant identiﬁ-
cation, tripeptidyl peptidase I activity in patient leucocytes
was found to be at the upper boundary of the affected
range. The above cases demonstrate the spectrum of sever-
ity associated with IEM and how common it is for clin-
icians investigating neurometabolic disorders to be
misguided by investigation results, with resulting diagnostic
delays. For example, an abnormal transferrin pattern com-
bined with neurological dysfunction would prompt investi-
gations for congenital disorders of glycosylation (Scott
et al., 2014), which was the case in Patient U8 in whom
variants in GALE were identiﬁed and UDP-galactose
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4’-epimerase activity was subsequently found to be
undetectable.
Apart from expanding the phenotypic spectrum of ‘well-
described’ disorders, our results help expand the genotypic
and phenotypic spectrum of recently described genetic con-
ditions including PGAP2 (Hansen et al., 2013; Krawitz
et al., 2013), ACSF3 (Sloan et al., 2011), DPYS (van
Kuilenburg et al., 2010), AFG3L2 (Pierson et al., 2011)
and SERAC1 (Wortmann et al., 2012). Hence, panel
approaches enable clinicians to establish diagnoses in
(and increase awareness of) ever broadening phenotypes
and recently-described disorders, while at the same time
circumventing problematic heterogeneity issues and poten-
tially shortening the time to establish a deﬁnitive diagnosis
for some patients.
Some patients with IEM have defects in more than one
gene contributing to observed phenotypes. Patient U7 had
mutations in ALDOB and TPP1. While mutations in
ALDOB have been associated with abnormal transferrin
patterns (Adamowicz et al., 2007), the majority of clinical
features seen in this case are likely attributable to the TPP1
mutation (Breedveld et al., 2004; Sun et al., 2013).
Similarly, Patients B6 and B7 had mutations in AASS,
which would explain the hyperlysinaemia seen in both
plasma and CSF but not the presence of developmental
delay, microcephaly, hypotonia and epilepsy (Houten
et al., 2013). Patient U2 had mutations in DPYS, which
are associated with abnormal purine and pyrimidine metab-
olites but not with dysplastic kidneys, eczema, microceph-
aly and developmental delay (van Kuilenburg et al., 2010).
The phenotypic features in these patients are most likely
attributable to other, yet unidentiﬁed, genetic defects. The
existence of pathogenic variants at two genetic loci in one
patient is not surprising, as individuals have 3.5 million
variants in their genome (Gonzaga-Jauregui et al., 2012). A
recent genetic study showed that 4.6% of participants had
blended phenotypes resulting from two single gene defects
(Yang et al., 2014). The above issues further complicate the
diagnosis of IEM and highlight the utility of NGS, espe-
cially in highly heterogeneous disorders while emphasizing
the need for diagnosticians to perform elaborate clinical
phenotyping and not over-rely on sequencing results, espe-
cially when identiﬁed gene defects do not account fully for
the observed clinical picture.
Despite our panel’s usefulness, there were also limitations
in our approach. No potential disease-causing gene alter-
ations were identiﬁed in 14/30 patients. While established
metrics indicate that our capture efﬁciency and depth of
coverage was good overall (Supplementary Table 3), muta-
tions may have been missed because of less efﬁcient capture
of GC-rich regions or low coverage due to sample complex-
ity. It is also plausible that the disease-causing genes were
not included in our design or that the causative mutations
were intronic or within regulatory regions. We were also
unable to identify the second pathogenic variant in Patient
B3 (CPS1 deﬁciency), possibly because it lies within exon
21 (regions of which were only covered at a read depth ofT
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3 ), an intronic area or a promoter region. More research
including WES or WGS in mutation-negative cases is war-
ranted to reach further conclusions. Overall, our ﬁndings
agree with previous studies indicating that, when analysed
by NGS, targeted genetic regions can be inconsistently cov-
ered at read depths sufﬁcient for comprehensive variant
analysis (Dewey et al., 2014). Additionally, although able
to identify deletions, we were unable to detect the homo-
zygous 111 bp deletion in Patient D6 or insertion/deletion
event in Patient B9, which highlights the challenges of using
NGS to detect copy number variants (Mullaney et al.,
2010). Indeed, some common pathogenic alleles can be
missed by conventional sequencing approaches, including
targeted NGS, unless methods are speciﬁcally adapted or
additional assays are included to capture them. These can
include deep intronic splice variants as in leukoencephalo-
pathy with brainstem and spinal cord involvement and lac-
tate elevation (van Berge et al., 2014) or whole gene
deletions and duplications as in Pelizaeus-Merzbacher dis-
ease (Lee et al., 2006).
Finally, detection of variants of uncertain signiﬁcance
could pose a diagnostic and ethical issue, especially in
patients with speciﬁc phenotypes where more targeted gen-
etic testing could be a reasonable alternative. We ﬁrstly
addressed this by following a ‘panel within a panel’
approach, initially interrogating genes in which mutations
were likely to result in the observed phenotypes (e.g. MUT,
MCEE, ACSF3, ALDH6A1, MMAA, MMAB, SUCLA2,
LMBRD1, ABCD4, MMADHC and MMACHC in patients
with methylmalonic aciduria) and expanding our search
when no likely pathogenic variants were identiﬁed.
Moreover, during the consenting process, we speciﬁcally
counselled all study participants that they would not be
informed about variants that were not deemed relevant to
the clinical presentation. Utilizing expert phenotyping, cur-
rent guidance on variant interpretation (Richards et al.,
2015) and close collaboration between clinicians and
scientists interrogating the data is crucial for the above to
be successfully implemented. Nevertheless, our study
shows that such approaches are feasible, even in pa-
tients with more speciﬁc clinical and/or biochemical pheno-
types. This approach is particularly applicable in various
neurometabolic conditions (such as the cases of peroxi-
somal biogenesis disorders and congenital disorders of gly-
cosylation in our cohort), where mutations in a large
number of genes could lead to similar biochemical
abnormalities.
We also encountered difﬁculties when utilizing in silico
tools for novel missense variant interpretation. When using
SIFT and PolyPhen-2 interpretation, discordance was occa-
sionally evident, not only for novel variants but also for
common variants of established pathogenicity in ASL
(Linnebank et al., 2002) and GALT (Reichardt et al.,
1992) (Tables 2 and Supplementary Table 1). However, des-
pite this discordance, CADD scores for these variants rank
them more deleterious than 99.5% of all possible human
single nucleotide variants. Additionally, SIFT, PolyPhen-2
and CADD suggested that a known pathogenic IDUA vari-
ant (Bach et al., 1993) was not likely to be deleterious
(Supplementary Table 1). Inability of online prediction
tools, particularly those using sequence-based algorithms,
to predict pathogenicity of all variants analysed correctly
has been evaluated previously (Castellana and Mazza,
2013; Dong et al., 2015; Walters-Sen et al., 2015). In
silico tools remain invaluable in ﬁltering large numbers
of variants identiﬁed using NGS platforms; however, fur-
ther evidence to support or refute pathogenicity should
be sought (Richards et al., 2015), for example segrega-
tion analysis and enzymatic assays in appropriate patient
tissues. In our study, we further characterized identiﬁed mis-
sense variants by mapping them to 3D protein structures
where possible. All variants were predicted to be deleterious
and probably/possibly damaging by SIFT and PolyPhen-2
and structural analysis supported these predictions in all
cases, providing further evidence of pathogenicity. Should
3D structural information become available for larger parts
of the human exome, this approach could become a valuable
aid towards novel variant analysis (Yue et al., 2014).
Extended panel approaches have gained popularity and
are used by many clinical laboratories in the investigation
of a wide range of genetically heterogeneous conditions
(http://www.labs.gosh.nhs.uk/media/759058/goshome_v7.p
df) including neurometabolic disease. With decreasing NGS
costs and the advent of the Genomics England 100 000
Genomes Project, WES and WGS will likely supersede the
use of gene panels in the clinical diagnostic setting in the
future. However, many challenges remain prior to this im-
plementation, including difﬁculties in interpreting over-
whelming amounts of data generated and uncertainties
about clinically reportable ﬁndings (Dewey et al., 2014).
Moreover, WES and WGS have proven invaluable in the
identiﬁcation of novel genes (Saitsu et al., 2013; Howard
et al., 2014) but such ﬁndings are not currently actionable
within the diagnostic setting. Elucidating the signiﬁcance of
these variants is not possible without functional character-
ization in appropriate settings and models, which is often
expensive and beyond the capacity of most clinical diag-
nostic laboratories. Until such challenges are surpassed,
gene panel approaches provide a rapid and cost-effective
method of testing patients with neurometabolic disorders
and enable more timely diagnosis and prompt treatment
initiation in these conditions.
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